Lu-PSMA clinical trials
Lu-PSMA is named as an intervention in 25 current clinical trials in our USA, France, Germany, Spain, Canada, Australia, Austria, Italy, UK, Netherlands, Czechia, China, Singapore, Israel, Belgium, Switzerland, Taiwan, South Korea, Sweden, Brazil, Mexico, Japan, Poland and Denmark registers. 9 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Novartis Pharmaceuticals (10). The most-studied condition is Prostate Cancer.
Patient leaflets for Lu-PSMA
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Lu-PSMA
25 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Lu-PSMA
19 conditionsAll 19 conditions
| Condition (as registered) | Trials |
|---|---|
| Prostate Cancer | 6 |
| Metastatic Castration-resistant Prostate Cancer | 3 |
| Prostatic Neoplasms | 2 |
| Metastatic Castration-Resistant Prostate Cancer | 2 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2 |
| Oligometastatic Prostate Cancer (OMPC) | 1 |
| Prostatic Neoplasm | 1 |
| Metastatic Castration Resistant Prostate Cancer (mCRPC) | 1 |
| Prostatic Cancer, Castration-Resistant | 1 |
| Metastatic Neuroendocrine Prostate Cancer | 1 |
| Prostate Cancer Patients | 1 |
| Metastatic Clear Cell Renal Cell Carcinoma | 1 |
| Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 1 |
| Metastatic Hormone Naive Prostate Cancer | 1 |
| mCRPC | 1 |
| Metastatic Prostate Cancer | 1 |
| Cancer | 1 |
| Prostate Cancer Recurrent | 1 |
| Oligometastatic Prostate Cancer | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 10 |
| Peter MacCallum Cancer Centre, Australia | 4 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2 |
| Medical University of Vienna | 2 |
| Hospices Civils de Lyon | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Canadian Cancer Trials Group | 1 |
| Jean-Mathieu Beauregard | 1 |
| Dana-Farber Cancer Institute | 1 |
| Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Lu-PSMA trials
How many clinical trials are testing Lu-PSMA?
25 current trials in our USA, France, Germany, Spain, Canada, Australia, Austria, Italy, UK, Netherlands, Czechia, China, Singapore, Israel, Belgium, Switzerland, Taiwan, South Korea, Sweden, Brazil, Mexico, Japan, Poland and Denmark registers name Lu-PSMA (also registered as AAA617) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.
Are Lu-PSMA trials recruiting patients?
Yes. 9 of the 25 trials are recruiting: 2 with sites in USA, 4 with sites in France, 2 with sites in Germany, 2 with sites in Spain, 3 with sites in Canada, 2 with sites in Australia, 4 with sites in Austria, 2 with sites in Italy, 2 with sites in UK, 2 with sites in Netherlands, 2 with sites in Czechia, 1 with sites in China, 1 with sites in Singapore, 2 with sites in Israel, 2 with sites in Belgium, 1 with sites in Switzerland, 1 with sites in Taiwan, 1 with sites in Sweden, 1 with sites in Brazil, 1 with sites in Mexico and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Lu-PSMA clinical trials?
Novartis Pharmaceuticals (10), Peter MacCallum Cancer Centre, Australia (4), Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (2) and Medical University of Vienna (2), among 11 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lu-PSMA works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lu-PSMA works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lu-PSMA (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.